Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pemafibrate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Kowa and DKSH Debut Triglycerides Lowering Medicine, Parmodia®, in Malaysia
Details : DKSH will undertake the responsibility for providing comprehensive Market Expansion Services for triglycerides lowering drug, Parmodia (pemafibrate).
Product Name : Parmodia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2025
Lead Product(s) : Pemafibrate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Pemafibrate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kowa To Discontinue K-877 (Pemafibrate) "Prominent" Cardiovascular Outcomes Study
Details : K-877 (pemafibrate), a highly potent and selective peroxisome proliferator activator receptor-alpha modulator for treatment of hyperlipidemia in Japan under brand name PARMODIA, will discontinue by DSMB who concluded that primary endpoint was unlikely to...
Product Name : K-877
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Pemafibrate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary efficacy endpoint met and studied was summed pain intensity difference from 0 to 48 hours (SPID0-48). SEGLENTIS (celecoxib) had a significantly greater effect on SPID0-48 (least-squares mean: −139.1 than tramadol, celecoxib or placebo.
Product Name : Seglentis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable